Thoracic aortic aneurysm in patients with loss of function Filamin A mutations: Clinical characterization, genetics, and recommendations.
Thoracic aortic aneurysm in patients with loss of function Filamin A mutations: Clinical characterization, genetics, and recommendations.
复制标题
功能丝A突变损失的患者的胸动脉瘤:临床表征,遗传学和建议。
DOI:
10.1002/ajmg.a.38580
复制
发表时间:
2018-03
期刊:
影响因子:
--
通讯作者:
Walsh CA
中科院分区:
文献类型:
--
作者:
Chen MH;Choudhury S;Hirata M;Khalsa S;Chang B;Walsh CA
The frequency and gender distribution of thoracic aortic aneurysm as a cardiovascular manifestation of loss-of-function (LOF) X-linked FilaminA (FLNA) mutations are not known. Furthermore, there is very limited cardiovascular morbidity or mortality data in children and adults. We analyzed cardiac data on the largest series of 114 patients with LOF FLNA mutations, both children and adults, with periventricular nodular heterotopia (PVNH), including 48 study patients and 66 literature patients, median age of 22.0 years (88F, 26M, range: 0 – 71 years), with 75 FLNA mutations observed in 80 families. Most (64.9%) subjects had a cardiac anomaly or vascular abnormality (80.8% of males and 60.2% of females). Thoracic aortic aneurysms (TAA) were found in 18.4% (n= 21), and were associated with other structural cardiac malformations in 57.1% of patients, most commonly patent ductus arteriosus (PDA) and valvular abnormalities. TAA most frequently involved the aortic root and ascending aorta, and were associated with sinus of Valsalva aneurysms in almost half. Six TAA patients (28.5%) required surgery (median age 37 yrs, range 14 – 41). TAA was also the only recorded cause of premature, non-accidental mortality in adults (2M, 2F), with unanticipated aortic rupture found on autopsy in 2 adult patients (1F, 1M, median 38.5 yrs), at aortic dimensions smaller than current recommendations for surgery for other aortopathies. Data from this largest series of LOF FLNA mutation patients underscore the importance of serial follow-up to identify and manage these potentially devastating cardiovascular complications.
登录
查看更多内容
影响因子:
16.2
作者:
Eksioglu, YZ;Scheffer, IE;Walsh, CA
通讯作者:
Walsh, CA
影响因子:
5.4
作者:
Lindsay, Mark E.;Dietz, Harry C.
通讯作者:
Dietz, Harry C.
DOI:
10.1056/nejmoa1404731
发表时间:
2014-11-27
期刊:
The New England journal of medicine
影响因子:
--
作者:
Lacro RV;Dietz HC;Sleeper LA;Yetman AT;Bradley TJ;Colan SD;Pearson GD;Selamet Tierney ES;Levine JC;Atz AM;Benson DW;Braverman AC;Chen S;De Backer J;Gelb BD;Grossfeld PD;Klein GL;Lai WW;Liou A;Loeys BL;Markham LW;Olson AK;Paridon SM;Pemberton VL;Pierpont ME;Pyeritz RE;Radojewski E;Roman MJ;Sharkey AM;Stylianou MP;Wechsler SB;Young LT;Mahony L;Pediatric Heart Network Investigators
通讯作者:
Pediatric Heart Network Investigators
影响因子:
16.2
作者:
Fox, JW;Lamperti, ED;Walsh, CA
通讯作者:
Walsh, CA
影响因子:
3.2
作者:
Nakamura, Fumihiko;Stossel, Thomas P.;Hartwig, John H.
通讯作者:
Hartwig, John H.